Trial Profile
A 52-week multicenter, open-label, randomized, parallel, two - arm study comparing Exubera (inhaled human insulin) vs. Humalog (insulin lispro), both in combination with insulin glargine in subjects with type 1 diabetes mellitus
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Insulin (Primary) ; Insulin glargine; Insulin lispro
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Pfizer
- 03 Apr 2022 Trial has been completed in Netherland (End Date: 30 Jun 2008), according to European Clinical Trials Database record.
- 18 Aug 2009 Actual patient number changed from 86 to 58 as reported by ClinicalTrials.gov.
- 07 Oct 2008 Planned end date changed from 1 Jan 2009 to 1 Jun 2008 as reported by ClinicalTrials.gov.